Subject characteristics
| Men | Women | p Value | |
|---|---|---|---|
| SPECT, single photon emission computed tomography; sUPDRS-III, selection of items of the Unified Parkinson’s Disease Rating Scale III. | |||
| Values are mean (range) unless otherwise stated. | |||
| Age at disease onset (y) | 51.3 (25–77) | 53.4 (28–74) | 0.06 |
| Age at time of first sUPDRS-III (y) | 53.4 (28–79) | 54 (31–75) | NS |
| Age at time of SPECT (y) | 52.8 (35–72) | 54.2 (31–68) | NS |
| Disease duration at time of first sUPDRS-III (y) | 2.5 (0.4–9.9) | 2.7 (0.2–10.0) | NS |
| Disease duration at time of SPECT (y) | 4.3 (0.7–9.9) | 4.3 (1.6–8.5) | NS |
| No of subjects in age at onset and symptom analysis | 156 | 97 | |
| No of subjects in sUPDRS-III analysis | 156 | 97 | |
| No of subjects in SPECT analysis | 74 | 36 | NS |
| Proportion (%) of patients taking | |||
| Selegiline | 25.2 | 24.2 | NS |
| Amantadine | 26.6 | 22.1 | NS |
| Orphenadrine | 7.2 | 9.3 | NS |